Skip to search formSkip to main contentSkip to account menu

SCH 351125

Known as: SCH-351125, SCH351125 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Ancriviroc

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Establishment of a new cell line for high-throughput evaluation of chemokine CCR5 receptor antagonists.
Chemokine receptors belong to a superfamily of proteins that signal through coupled heterotrimeric G proteins. Chemokine receptor… 
2005
2005
Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists.
2003
2003
Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides.
2003
2003
Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.
Highly Cited
2002
Highly Cited
2002
Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4… 
Review
2002
Review
2002
Non-peptidic Chemokine Receptors Antagonists as Emerging Anti-HIV Agents
HIV entry within the cell involves the presence of at least two chemokine co-receptors, the CCR5 and CXCR4 receptors. Viral entry… 
Highly Cited
2001
Highly Cited
2001
Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for…
Structure-activity studies on piperidino-piperidine 3 led to the discovery of SCH 351125 (1), a selective CCR5 antagonist with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)